Skip to main content
Premium Trial:

Request an Annual Quote

National Human Genome Center of Shanghai Sees Company Born

NEW YORK, Sept. 4 - Shanghai IgCon Therapeutics, a joint venture of Genetastix and the South Gene Technology Company, got the official green light to begin operations from the Shanghai municipal government, the companies said today.

 

Shanghai IgCon Therapeutics, established last November, will focus on pre-clinical and clinical development of human therapeutic antibodies for the Chinese and Asian markets, according to the company.

 

The South Gene Technology Company is the commercial arm of the National Human Genome Center of Shanghai, which was established in 1998.

 

Genetastix is based in San Jose, Calif.

 

For further information, see the press release.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.